BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has Been Awarded To Date Under The Contract
September 18, 2014 at 12:08 PM EDT
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has ...